ImmuneOnco Biopharmaceuticals (Shanghai) Inc (1541) Fair Value & Analysis
Healthcare · HK · Market cap HK$1.7B
Fair value as of: Aug 5, 2026
From 1 valuation models · updated 5 days ago
Fair value updated Aug 5, 2026, revised from HK$1.68 to HK$1.67 (−0.6%) since Jul 2, 2026. Share price −8.8% over the past month.
Below-average quality, and screening another 47% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (HK$2.09). The favourable scenario is already priced in.
- Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (HK$1.10 to HK$2.09) leaves room in how you read the outcome.
Price vs Fair Value (3 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 5, 2026.
How to read this chart
35‑month range HK$2.91 – HK$31.05 · fair‑value band HK$1.10 – HK$2.09 · the HK$3.16 price screens above the HK$1.67 fair value. Dashed = 300-day average. As of Aug 5, 2026.
Analysis
ImmuneOnco Biopharmaceuticals (Shanghai) Inc (1541) currently trades at HK$3.16, while our model-based Fair Value estimate is HK$1.67, implying the stock looks roughly 47.1% overvalued today. The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at HK$154M. Revenue grew 50.2% year over year. It earns a return on equity of -29.9%. The balance sheet holds a net cash position of HK$452M. Fundamentals as of Aug 5, 2026
Our scenario range runs from HK$1.10 (bear case) to HK$2.09 (bull case); at HK$3.16, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -47%, 1541 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when 1541 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 5, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 43 · Market factors (momentum, volatility) 17
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in China and the United States.
Full company description
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in China and the United States. The company's core product candidate is IMM01, which is in Phase Ib/IIa clinical trial to evaluate the combination with bortezomib and dexamethasone for the treatment of multiple myeloma; Phase II clinical trial in combination with azacitidine for the first-line treatment of higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia; and Phase III clinical trial in combination with tislelizumab, targeting relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) patients who relapsed or progressed after the treatment of PD-1 inhibitors. It also develops IMM0306 that is in Phase Ib/IIa clinical trial for the treatment of R/R CD20-positive B-cell non-Hodgkin lymphoma (B-NHL); IMM2510, which is in Phase Ib/IIa clinical trial to treat R/R soft tissue sarcoma; IMM27M that in Phase Ib/II clinical trial to treat solid tumors; and IMM2520, which is in Phase I clinical trial for solid tumors. In addition, the company develops IMC-002 for treating autoimmune indications; IMC-001 for the treatment of atherosclerosis; IMM72; IMM7211b; IMM51, IMM38, IMM50, and IMM62 for solid tumors; and IMM40H for liquid/solid tumors. It has license and collaboration agreement with Instil Bio, Inc. for the development of IMM2510 and IMM27M. ImmuneOnco Biopharmaceuticals (Shanghai) Inc. was incorporated in 2015 and is headquartered in Shanghai, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
ImmuneOnco Biopharmaceuticals (Shanghai) Inc reported revenue of HK$150M in FY2025 versus HK$13.8M in FY2021, a compound +81.6%/yr. Reported net income was −HK$213M in FY2025.
1541 screens 47% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 601 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare ImmuneOnco Biopharmaceuticals (Shanghai) Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is ImmuneOnco Biopharmaceuticals (Shanghai) Inc (1541) overvalued or undervalued?
What is the fair value of 1541?
What is the quality score of 1541?
What is the revenue of ImmuneOnco Biopharmaceuticals (Shanghai) Inc (1541)?
What is the net profit margin of 1541?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track ImmuneOnco Biopharmaceuticals (Shanghai) Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.